Access to medicines for all
Short Business Description:
Axmed is a B2B medicines marketplace transforming healthcare access for underserved communities worldwide. By consolidating demand across public, private, and third sectors, the platform enables bulk purchasing, reducing costs and improving supply chain efficiency. It connects pre-approved manufacturers with buyers, ensuring access to high-quality medicines at competitive prices. Through strategic partnerships with governments, NGOs, and logistics providers, Axmed streamlines procurement and distribution.
Axmed AG is a Basel-based company reshaping how medicines are accessed in low- and middle-income countries (LMICs). As a B2B digital marketplace, Axmed streamlines the procurement and delivery of pharmaceutical products by consolidating demand across public, private, and non-profit sectors. This approach not only drives efficiency and reduces costs, but also ensures that life-saving medicines, ranging from essential generics to innovative therapies, reach underserved populations more reliably.
At the core of Axmed’s model is a platform that aggregates demand from multiple buyers and connects them with pre-approved manufacturers. This aggregation enables larger order volumes, which in turn unlocks better pricing and improves the availability of high-quality medicines. The platform also integrates logistics through partnerships with leading service providers, offering end-to-end visibility and dependable delivery to a wide variety of destinations.
Access to affordable, high-quality medicines remains one of the most urgent challenges in global health. Fragmented supply chains, inflated pricing, and inconsistent delivery have long hindered efforts to improve healthcare outcomes in LMICs. Axmed directly addresses these systemic issues by creating a transparent, scalable procurement solution that benefits both suppliers and local healthcare systems.
The company’s goal over the next five years is to reduce the number of people without access to essential medicines by at least one-third. Impact will be measured through clear indicators such as the number of medicines delivered, cost savings for buyers, geographic expansion, and strengthened partnerships with suppliers and health providers.
Leading Axmed is co-founder and CEO Emmanuel Akpakwu, whose background in global healthcare strategy, pharmaceutical operations and on-the-ground experience informs the company’s practical, mission-driven approach. Under his leadership, Axmed combines commercial expertise with a strong social purpose – building resilient supply systems that can adapt to future health needs and market shifts.
With over two billion people worldwide lacking adequate access to medicines, and with LMICs spending over $100 billion annually on pharmaceuticals, Axmed is positioned at the intersection of global health impact and significant market opportunity.